ALK-abello (0OIR) Share Price & Analysis

0OIR Stock Chart & Stats

DKK 248.30DKK 1.70(0.69%)

At close: Oct 30 12:00 AM GMT

Day’s Range: DKK 248.00 - DKK 249.64
52-Week Range: DKK 191.90 - DKK 271.60
Previous Close: DKK 246.60
Volume: N/A
Average Volume (3M): 36.66K
Market Cap: DKK 55.21B
Enterprise Value: DKK 52.87B
Total Cash (Recent Filing): DKK 316.00M
Total Debt (Recent Filing): DKK 990.00M
Price to Earnings (P/E): 40.7
Beta: 0.41
Next Earnings: Nov 17, 2026 (Est.)
EPS Estimate: 1.7
Next Dividend Ex-Date: N/A
Dividend Yield: 0.65%

ALK-abello News

ALK-Abelló Earnings Call Highlights Growth Amid Risks

ALK-abello A/S Class B (($DK:ALK.B)) has held its Q2 earnings call. Read on for the main highlights of the call. ALK-Abelló’s latest earnings call struck an upbeat tone as management

2M agoAKBLF 4AJ0

AKBLF Earnings Report this Week: Is It a Buy, Ahead of Earnings?

ALK-abello A/S Class B (AKBLF) is scheduled to report 2nd quarter earnings on 08/20/2026. Regarding Q2 estimates, Wall Street analysts expect ALK-abello A/S Class B to post earnings of DKK1.50

2M agoAKBLF 4AJ0

ALK-Abello initiated with a Buy at Berenberg

Berenberg initiated coverage of ALK-Abello (AKBLF) with a Buy rating and DKK 305 price target The firm says ALK is the global market leader in allergy immunotherapy. Published first on

5M agoAKBLF 4AJ0

ALK-Abelló Lifts Outlook After Strong Q1 Call

ALK-abello A/S Class B (($DK:ALK.B)) has held its Q1 earnings call. Read on for the main highlights of the call. ALK-Abelló’s latest earnings call struck an upbeat tone as strong

6M agoAKBLF 4AJ0

ALK-Abelló Earnings Call Signals Profitable Growth

ALK-abello A/S Class B (($DK:ALK.B)) has held its Q4 earnings call. Read on for the main highlights of the call. ALK‑Abelló’s latest earnings call struck an upbeat tone, underscoring a

8M agoAKBLF 4AJ0

ALK-Abelló Reports Strong Q3 Growth and Upgrades Outlook

ALK-abello A/S Class B ( ($AKBLF) ) has released its Q3 earnings. Here is a breakdown of the information ALK-abello A/S Class B presented to its investors. ALK-Abelló A/S, a

11M agoAKBLF 4AJ0

ALK-abello A/S Earnings Call Highlights Growth and Challenges

ALK-abello A/S Class B (($DK:ALK.B)) has held its Q3 earnings call. Read on for the main highlights of the call. The recent earnings call for ALK-abello A/S Class B painted

11M agoAKBLF 4AJ0

Is AKBLF a Buy, Before Earnings?

ALK-abello A/S Class B (AKBLF) is scheduled to report 3rd quarter earnings on 11/13/2025. Regarding Q3 estimates, Wall Street analysts expect ALK-abello A/S Class B to post earnings of DKK1.00

11M agoAKBLF 4AJ0

ALK-abello Earnings Call: Strong Growth Amid Challenges

ALK-abello A/S Class B (($DK:ALK.B)) has held its Q2 earnings call. Read on for the main highlights of the call. The recent earnings call for ALK-abello A/S Class B painted

1y agoAKBLF 4AJ0

ALK-Abelló A/S Reports Strong Q2 2025 Earnings Growth

ALK-abello A/S Class B ( ($AKBLF) ) has released its Q2 earnings. Here is a breakdown of the information ALK-abello A/S Class B presented to its investors. ALK-Abelló A/S, a

1y agoAKBLF 4AJ0

ALK-abello A/S Class B (AKBLF) Q2 Earnings Cheat Sheet

ALK-abello A/S Class B (AKBLF) is scheduled to report 2nd quarter earnings on 08/21/2025. Regarding Q2 estimates, Wall Street analysts expect ALK-abello A/S Class B to post earnings of DKK1.30

1y agoAKBLF 4AJ0

ARS Pharmaceuticals Air Lease ALK-Abello

ARS Pharmaceuticals (SPRY) announced that the company has entered into an agreement with ALK-Abello A/S (AKBLF) to co-promote neffy, the only approved needle-free treatment for Type I allergic reactions including

1y agoSPRY AKBLF

ALK-Abello says FDA approves label expansion for Odactra

ALK announced that the U.S. FDA expanded its indication of Odactra for the treatment of house dust mite-induced allergic rhinitis, with or without conjunctivitis, to now include children ages 5

1y agoAKBLF 4AJ0

ALK-Abello upgraded to Buy from Hold at Jefferies

Jefferies upgraded ALK-Abello (AKBLF) to Buy from Hold with a price target of DKK 185, up from DKK 153. The firm has become more positive on ALK’s growth profile, saying

1y agoAKBLF 4AJ0

0OIR FAQ

What was ALK-abello’s price range in the past 12 months?

ALK-abello lowest share price was kr 191.90 and its highest was kr 271.60 in the past 12 months.

What is ALK-abello’s market cap?

ALK-abello’s market cap is kr 55.21B.

When is ALK-abello’s upcoming earnings report date?

ALK-abello’s next earnings report is estimated for Nov 17, 2026 (not yet confirmed), which is in 15 days.

How were ALK-abello’s earnings last quarter?

ALK-abello released its earnings results on Aug 20, 2026. The company reported kr 1.5 earnings per share for the quarter.

Is ALK-abello overvalued?

Not enough analysts have published a price target to calculate whether the price is overvalued.

Does ALK-abello pay dividends?

ALK-abello does not currently pay dividends.

What is ALK-abello’s EPS estimate?

ALK-abello’s EPS estimate is 1.70.

How many shares outstanding does ALK-abello have?

ALK-abello has 202,567,200 shares outstanding.

What happened to ALK-abello’s price movement after its last earnings report?

ALK-abello reported an EPS of kr 1.5 in its last earnings report. Following the earnings report the stock price went down -4.182%.

Which hedge fund is a major shareholder of ALK-abello?

Hedge funds hold ALK-abello shares: the largest hedge-fund position in ALK-abello is 933,833,214 shares, and hedge funds increased their holdings by 3.0K shares last quarter.

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

ALK-abello

ALK-Abelló A/S is a global leader in allergy solutions, with operations spanning Europe, North America, and other international regions. The company offers a comprehensive portfolio of treatments for allergic rhinitis and allergic asthma, featuring key products such as GRAZAX/GRASTEK, RAGWITEK/RAGWIZAX, ACARIZAX/ODACTRA, MITICURE, CEDACURE, and ITULAZAX. ALK-Abelló specializes in allergy immunotherapy, providing options like injections, sublingual drops, and tablets to address a wide range of sensitivities, including those to grass, ragweed, house dust mites, Japanese cedar, various tree pollens, and certain foods. Furthermore, the company engages with consumers through a digital healthcare ecosystem, a platform designed to connect with allergy sufferers early in their journey, offering tools, e-commerce solutions, and guidance to support and streamline access to immunotherapy. ALK-Abelló also provides essential diagnostic allergy services, including skin prick and blood tests, alongside emergency treatments such as intramuscular adrenaline injections for severe, life-threatening allergic reactions like anaphylaxis. The company was established in 1923 and is based in Hørsholm, Denmark.

ALK-abello (0OIR) Earnings & Revenues

Historic Earnings Reports

0OIR Company Deck

0OIR Earnings Call

Q2 2026

0:00 / 0:00

Earnings Call SentimentPositive

The call emphasized strong top-line and cash-generation performance driven by tablet momentum, robust pipeline progress (peanut Phase III planning, China ACARIZAX readout) and an upgraded revenue range, while also acknowledging near-term cost increases and regulatory/market-access headwinds—most notably the German rebate increase and U.K. rollout delays for neffy. Management outlined mitigation plans and maintained long-term ambitions, suggesting confidence in growth despite some regional and timing uncertainties.

View all GB:0OIR earnings summaries

Technical Analysis

Overall Consensus

Indicator	Bullish	Neutral	Bearish
Overall Consensus	15	1	6
Technical Analysis	3	1	6
Moving Averages	12	0	0

Technical Analysis >

Similar Stocks

Stocks similar to GB:0OIR
Company	Price & Change	Follow
AKBLFALK-abello
INOInovio Pharmaceuticals
ACRSAclaris Therapeutics
EBSEmergent Biosolutions
NVSNovartis
BMYBristol-Myers Squibb

Compare GB:0OIR Stocks >

Ownership Overview

3.75% Mutual Funds
91.69% Public Companies and Individual Investors

Detailed Ownership Overview >

Popular Stocks

Popular Stocks
Company	Price & Change	Follow
NVDANvidia
AAPLApple
MSFTMicrosoft

0OIR Stock Chart & Stats

ALK-abello News

ALK-Abelló Earnings Call Highlights Growth Amid Risks

AKBLF Earnings Report this Week: Is It a Buy, Ahead of Earnings?

ALK-Abello initiated with a Buy at Berenberg

ALK-Abelló Lifts Outlook After Strong Q1 Call

ALK-Abelló Earnings Call Signals Profitable Growth

ALK-Abelló Reports Strong Q3 Growth and Upgrades Outlook

ALK-abello A/S Earnings Call Highlights Growth and Challenges

Is AKBLF a Buy, Before Earnings?

ALK-abello Earnings Call: Strong Growth Amid Challenges

ALK-Abelló A/S Reports Strong Q2 2025 Earnings Growth

ALK-abello A/S Class B (AKBLF) Q2 Earnings Cheat Sheet

ARS Pharmaceuticals Air Lease ALK-Abello

ALK-Abello says FDA approves label expansion for Odactra

ALK-Abello upgraded to Buy from Hold at Jefferies

0OIR FAQ

Company Description

ALK-abello

ALK-abello (0OIR) Earnings & Revenues

0OIR Company Deck

0OIR Earnings Call

Earnings Call Sentiment|Positive

Technical Analysis

Overall Consensus

Similar Stocks

Ownership Overview

Popular Stocks

Become an Expert with TipRanks Premium

Earnings Call SentimentPositive